Sunesis Pharmaceuticals (SNSS) : Noven Financial Group scooped up 34,167 additional shares in Sunesis Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 41,000 shares of Sunesis Pharmaceuticals which is valued at $170,970.Sunesis Pharmaceuticals makes up approximately 0.06% of Noven Financial Group’s portfolio.
Other Hedge Funds, Including , Jnba Financial Advisors added SNSS to its portfolio by purchasing 55 company shares during the most recent quarter which is valued at $229. Northeast Financial Consultants Inc sold out all of its stake in SNSS during the most recent quarter. The investment firm sold 3,583 shares of SNSS which is valued $13,544.Blackrock Fund Advisors boosted its stake in SNSS in the latest quarter, The investment management firm added 277 additional shares and now holds a total of 2,525 shares of Sunesis Pharmaceuticals which is valued at $9,545.Tci Wealth Advisors reduced its stake in SNSS by selling 1 shares or 4.17% in the most recent quarter. The Hedge Fund company now holds 23 shares of SNSS which is valued at $84.Winfield Associates reduced its stake in SNSS by selling 334 shares or 90.51% in the most recent quarter. The Hedge Fund company now holds 35 shares of SNSS which is valued at $128.
Sunesis Pharmaceuticals closed down -0.01 points or -0.24% at $4.1 with 45,116 shares getting traded on Monday. Post opening the session at $4.11, the shares hit an intraday low of $4.1 and an intraday high of $4.18 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Sunesis Pharmaceuticals reported $-0.62 EPS for the quarter, beating the analyst consensus estimate by $ 0.11 according to the earnings call on Nov 3, 2016. Analyst had a consensus of $-0.73. The company had revenue of $.60 million for the quarter, compared to analysts expectations of $.60 million. The company’s revenue was down -12.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.09 EPS.
Sunesis Pharmaceuticals Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company’s program is QINPREZOTM (vosaroxin) which is its product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD) which is a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin is an AQD which is used for the treatment of cancer. MLN2480 is an oral investigative drug selective for pan-Raf kinase inhibition in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). PDK1 is a kinase and mediator of PI3K/AKT signaling which is a pathway involved in cell growth differentiation survival and migration.